secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2026-07-29T10:15:13+00:00
Accession:  0000917520-26-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra Q2 2026: Revenue $418.8M (+0.8%), Adj EPS $0.56 vs $0.45; reaffirms FY adj EPS $2.40-$2.50
--------------------------------------------------------------------------------

- Q2 revenue $418.8M (+0.8% reported, +0.7% organic); GAAP EPS $0.06 vs -$6.31; adjusted EPS $0.56 vs $0.45.
- Adjusted EBITDA $78.4M (18.7% of revenue) vs $71.2M (17.1%) in prior year.
- Specialty Surgery revenue $309.3M (+1.6% organic); Tissue Reconstruction $109.5M (-2.0% organic).
- Full-year reported revenue guidance narrowed to $1.654B-$1.695B (from $1.662B-$1.702B) due to FX; organic growth and adj EPS reaffirmed.
- Braintree facility producing; SurgiMend relaunch on track for Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000055/0000917520-26-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000055/iart-20260729.htm
  HTML page:      https://secwatch.observer/filing/0000917520-26-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer